Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed ...

Dr. David N. Cade, Telix Group Chief Medical Officer, added, "We are pleased that a first patient has been imaged in the first-in-human ZOLAR trial, which is designed to inform both the potential ...

Dr. David N. Cade, Telix Group Chief Medical Officer, added,“We are pleased that a first patient has been imaged in the first-in-human ZOLAR trial, which is designed to inform both the potential ...

Dr. David N. Cade, Telix Group Chief Medical Officer, emphasized the importance of the trial in determining the candidate’s potential efficacy and safety profile. STS is a group of rare cancers ...